Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length
复制标题
DOI：
10.1002/jps.20201
复制
发表时间：
2004-11-01
影响因子：
3.8
通讯作者：
Raper, JA
中科院分区：
文献类型：
--
作者：
Coates, MS;Fletcher, DF;Raper, JA
本研究调查了（1）修改干粉吸入器设计对设备性能的影响，以及（2）哪些设计特征对吸入器的整体性能有显着贡献。进行计算流体动力学 (CFD) 分析，以确定当吸入器网格和吸嘴被修改时，Aerolizer(R) 在 601 分钟(-1) 时产生的流场如何变化。计算模型通过激光多普勒测速（LDV）进行了验证。使用多级液体冲击器在 601 分钟(-1) 时用甘露醇粉末测量改进的吸入器的分散性能。研究发现吸入器网格对 Aerolizer(R) 的性能有显着影响。随着网格空隙率的增加，装置中保留的粉末量加倍（由于吸入器接口中颗粒的切向流动增加），并且 FPFLoaded 从 57% 减少到 44%（由于接口保留增加）。吸嘴的长度对吸入器性能的影响较小，对装置中产生的流场没有显着影响。总之，简单的设计改变就会影响干粉吸入器的性能。 CFD 与实验结果相结合，为理解性能差异提供了合理的基础。 (C) 2004 Wiley-Liss, Inc. 和美国药剂师协会。
This study investigates (1) the effect of modifying the design of a dry powder inhaler on the device performance, and (2) which design features significantly contribute to overall inhaler performance. Computational Fluid Dynamics (CFD) analysis was performed to determine how the flowfield generated in an Aerolizer(R) at 601 min(-1) varied when the inhaler grid and mouthpiece were modified. The computational models were validated by Laser Doppler Velocimetry (LDV). Dispersion performance of the modified inhalers was measured with a mannitol powder using a multistage liquid impinger at 601 min(-1). The inhaler grid was found to significantly affect the performance of the Aerolizer(R). As the grid voidage was increased, the amount of powder retained in the device doubled (due to increased tangential flow of particles in the inhaler mouthpiece) and the FPFLoaded was reduced from 57 to 44% (due to increased mouthpiece retention). The length of the mouthpiece played a lesser role on the inhaler performance, having no significant effect on the flowfield generated in the devices. In summary, the performance of a dry powder inhaler can be affected by simple design changes. CFD, coupled with experimental results, provides a rational basis for understanding the performance difference. (C) 2004 Wiley-Liss, Inc. and the American Pharmacists Association.